While this study provides insights into the cardioprotective effects of SGLT2 inhibitor treatment, it does not determine the suitability of SGLT2 inhibitors for patients with obesity-induced MHD. This evidence concerns the gene SLC5A2 and obesity due to melanocortin 4 receptor deficiency.